Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DR-2001a · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| DR-2001a | DRUG | DR-2001a administered vaginally each month |
| DR-2001b | DRUG | DR-2001b administered vaginally each month |
| Placebo | OTHER | Placebo administered vaginally each month |
Inclusion Criteria: * Surgically sterilized (patient or partner), willing to use condoms throughout the study, or otherwise not at risk for pregnancy * Diagnosis of endometriosis within the last 5 years * Moderate or severe nonmenstrual pelvic pain * Premenopausal * Not pregnant or breastfeeding * ...
DR-2001a is being developed for the treatment of endometriosis. It is a small molecule in Phase 2 clinical development. The completed Phase 2 trial evaluated DR-2001 for the management of endometriosis-related pelvic pain in adult women.
DR-2001a is being developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. The company sponsored the Phase 2 clinical trial of the drug in endometriosis.
DR-2001a is in Phase 2 clinical development for endometriosis. It is an investigational small molecule and has not been approved by the FDA. One Phase 2 trial has been completed, and no trials are currently active.
DR-2001a has been studied in one completed Phase 2 trial, NCT00117481, titled Evaluation of DR-2001 for the Management of Endometriosis-Related Pelvic Pain. The trial enrolled 90 female participants aged 18 years and older in the United States.
The Phase 2 trial NCT00117481 was a randomized, double-blind, placebo-controlled study. It enrolled 90 female participants aged 18 years and older with endometriosis in the United States and has been completed. The trial evaluated DR-2001 for endometriosis-related pelvic pain.